ARTICLE | Clinical News

T-20: Phase I/II

February 5, 2001 8:00 AM UTC

In a U.S. Phase I/II trial of T-20 in 12 children, subcutaneous dosing of T-20 for up to 12 weeks was well tolerated, and children in the highest dose group (60 mg/m 2) had a 10-fold decrease in HIV R...